GlassScriptPhysician profile
Giang V Vu
NPI 1386733483
$8,861.69
in general payments reported to CMS, 2019-2025
38 companies · $3,282 in 2025
The $3,282 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $596 · 2022: $994 · 2023: $1,533 · 2024: $2,457 · 2025: $3,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,172 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,171.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,278.05 | 2021-2025 | |
| Axsome Therapeutics, INC. | $700.53 | 2024-2025 | Sunosi, Auvelity |
| Jazz Pharmaceuticals INC. | $640.29 | 2021-2025 | |
| Lilly USA, LLC | $618.91 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $577.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $414.21 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $372.64 | 2022-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $299.35 | 2023-2025 | Rexulti |
| Corcept Therapeutics | $257.23 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $239.23 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $238.41 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.52 | 2022-2025 | Jardiance |
| Amgen INC. | $230.07 | 2023-2025 | Otezla, Repatha, Otezla |
| Harmony Biosciences LLC | $223.41 | 2022-2025 | Wakix |
| Pfizer INC. | $181.15 | 2023-2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giang Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.